Determinant | Main effect | Selection criteria |
---|---|---|
Coverage | Tumor clearance efficiency | 1. It should be high enough, and it is possible to obtain CRR response using antibodies or CAR-T therapy against this target. 2. Refer to the efficacy of related antibody drugs. 3. Test patients’ samples before the treatment. |
Specificity | “Off-tumor” cytotoxicity | 1. It is limited to tumor tissue, or the damage caused by off-tumor toxicity can be tolerated or well managed. 2. Refer to the side effect of related antibody drugs. |
Stability | Response duration and recurrence | 1. The expression should be stable and not easily regulated by external signals. 2. It plays an important role in the growth and survival of cancer cells. |